首页> 中文期刊> 《疑难病杂志》 >比较通心络胶囊与复方丹参片治疗冠心病心绞痛有效性及安全性的系统评价

比较通心络胶囊与复方丹参片治疗冠心病心绞痛有效性及安全性的系统评价

         

摘要

目的 应用系统评价比较通心络胶囊与复方丹参片治疗冠心病心绞痛的有效性及安全性.方法 计算机检索Cochrane图书馆临床对照试验资料库(2011年第2期)、PubMed(1966-2011年6月)、Embase(1966-2011年6月)、中国期刊全文数据库(CNKI)(1979-2011年6月)、万方数字化期刊库(1981-2011年6月)、中国生物医学文献数据库(1989-2011年6月),按纳入与排除标准选择随机对照试验、评价质量,提取资料,并用RevMan 4.2软件对数据进行Meta分析.结果 初检出文献共196篇,经筛选最终纳入15篇关于通心络胶囊对比复方丹参片治疗冠心病心绞痛的随机对照研究.心绞痛疗效:通心络组优于复方丹参片组[χ2=9.01,95%CI(4.75,8.71),Z=12.03,P<0.01];心电图疗效:通心络组优于复方丹参片组[χ2=19.97,95%CI (2.88,4.66),Z=10.54,P<0.01].结论 通心络胶囊治疗冠心病心绞痛的疗效及安全性均优于复方丹参片.%Objective To compare the efficacy and safety between Tongxinluo capsule with Danshen tablet in the treatment of angina pectoris. Methods Electronic searches were performed by using the Cochrane Central Register of Controlled Trials ( Issue 2, 2011 ), PubMed ( from 1966 to June 2011 ), Embase ( from 1966 to June 2011 ), and CNKI ( from 1979 to June 2011 ), Wanfang Dadt( from 1981 to June 2011 ), CBM ( from 1989 to June 2011 ). Randomized controlled trials ( RCTs ) were used to screen the retrieved studies according to predefined inclusion and exclusion criteria, the quality of included studies was evaluated and RevMan 4. 2 software was used for Meta-analysis. Results A total of 196 articles were found and 15 of which were finally included. Therapeutic effects of angina pectoris was better in Tongxinluo group than Danshen group[ χ2 =9.01, 95% CI(4.75, 8.71 ),Z = 12.03, P <0. 01 ]. Electrocardiogram ( ECG )was better in Tongxinluo group than Danshen group[ χ2 = 19. 97, 95% CI ( 2. 88,4. 66 ), Z = 10. 54, P < 0. 01 ]. Conclusion The efficacy and safety of Tongxinluo capsule is better than Danshen tablet in treating patients with angina pectoris.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号